JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: We herein report a case of CML-myeloid BP with a long history of PV with JAK2 V617 F refractory to induction chemotherapy with TKIs, including dasatinib, nilotinib, and bosutinib, which responded well to asciminib combined with ropegIFNα2b.